Table 1.
Descriptive data for non-CKD subjects stratified in BMI subgroups and for CKD patients stratified in PD and HD subgroups
| BMI<18.5 | 18.5≤BMI<25 | 25≤BMI<30 | BMI≥30 | PD | HD | |
|---|---|---|---|---|---|---|
| n | 40 | 120 | 118 | 108 | 30 | 93 |
| Women (%) | 32 | 62 | 59 | 52 | 11 | 42 |
| (80) | (51) | (50) | (48) | (37) | (45) | |
| Age (years) | 26±4.2a | 29±3.9a | 29±4.6a | 30±5a | 52±19b | 47±13c |
| (20 to 38) | (20 to 40) | (20 to 40) | (20 to 40) | (15 to 81) | (20 to 76) | |
| Weight (kg) | 48±4.9a | 64±9.4b | 79±9.8c | 98±12d | 68±13be | 72±17e |
| (39 to 60) | (45 to 87) | (59 to 109) | (71 to 124) | (38 to 93) | (42 to 137) | |
| BMI (kg/m2) | 18±0.7a | 22±1.8b | 27±1.4c | 34±2.7d | 24±3.4e | 26±5e |
| (15 to 18) | (19 to 25) | (25 to 30) | (30 to 40) | (16 to 32) | (17 to 44) | |
| OH (L) | -0.1±0.4a | -0.3±0.7a | -0.5±0.9ab | -0.8±0.9b | 2.1±2.2c | -0.9±1.9b |
| (-1.2 to 0.9) | (-1.9 to 1.5) | (-3.1 to 2.1) | (-3 to 1.8) | (-0.7 to 6.2) | (-5 to 6.0) | |
| OH>1.1 L (%) | 0 | 0 | 4 | 3 | 17 | 10 |
| (0) | (0) | (3) | (3) | (57) | (11) | |
| OH<-1.1 L (%) | 0 | 14 | 29 | 42 | 0 | 49 |
| (0) | (12) | (25) | (39) | (0) | (53) | |
| FFM (kg) | 34±6.3a | 43±11b | 45±13b | 46±13b | 34±6.6a | 38±9.7a |
| (26 to 51) | (26 to 70) | (27 to 76) | (25 to 76) | (24 to 56) | (20 to 60) | |
| FFMI (kg/m2) | 12±1.5a | 15±2.8b | 15±3.1b | 15±3.1b | 12±1.8a | 14±2.6a |
| (10 to 16) | (9 to 22) | (10 to 23) | (9 to 23) | (8 to 16) | (8 to 20) | |
| FM (kg) | 14±4a | 21±7.1b | 34±9.3c | 52±12d | 30±12c | 34±16c |
| (4 to 21) | (3 to 37) | (11 to 57) | (24 to 83) | (9 to 56) | (2 to 99) | |
| FMI (kg/m2) | 5±1.5a | 7±2.7b | 12±3.5c | 18±4.6d | 11±4.2c | 12±5.6c |
| (1 to 8) | (1 to 13) | (4 to 19) | (8 to 29) | (4 to 19) | (1 to 29) | |
| PA (ₒ) | 5.8±0.5a | 6.6±0.8b | 6.8±0.8b | 6.8±0.8b | 4.7±1.1c | 6.1±1.2a |
| (4.8 to 7) | (4.8 to 8.2) | (5.3 to 9) | (5 to 8.9) | (2.8 to 7.1) | (3 to 9.1) | |
| Impairment Nutritional status (%)1 | 4 | 7 | 4 | 2 | 23 | 33 |
| (10) | (6) | (3) | (2) | (76) | (36) | |
| DM (%) | 0 | 0 | 0 | 0 | 10 | 61 |
| (0) | (0) | (0) | (0) | (33) | (66) | |
| SAH (%) | 0 | 0 | 0 | 0 | 19 | 61 |
| (0) | (0) | (0) | (0) | (63) | (66) | |
| Residual Diuresis (ml)2 | 937±680*** | 170±330*** | ||||
| (50 to 2000) | (0 to 2000) | |||||
| Kt/V1 | 2.6±0.9*** | 1.5±0.3*** | ||||
| (1.4 to 4.5) | (1 to 2.5) | |||||
| Duration of dialytic treatment | 33±32*** | 63±48*** | ||||
| (months)2 | (3 to 144) | (5 to 264) | ||||
| Dialytic treatment >12 months (%) | 21 | 82 | ||||
| (70) | (88) |
BMI, body mass index; CKD, chronic kidney disease; DM, Diabetes Mellitus; FFM, fat free mass; FFMI, fat free mass index; FM, fat mass; FMI, fat mass index; HD, hemodialysis; OH, overhydration; PA, phase angle; PD, peritoneal dialysis; SAH, Systemic Arterial Hypertension. Data presented as mean ± SD (minimum value to maximum value) or in %. Values with different letters in the same line between BMI subgroups, PD and HD groups are significantly different, p<0.05 (ANOVA). 1According to the obtained PA and the cut-off points proposed by Kuchnia and collaborators [24]. 2Data analyzed with unpaired t test, PD vs HD, ***p<0.001. FFM, FFMI, FM, FMI, OH and PA data from multifrequency bioelectrical impedance spectroscopy.